Skip to main content

Hamill John P.'s Form 4 filing

Aprea Therapeutics, Inc.APRE · filed Apr 1, 2026

Accession no.
0001104659-26-038522
Filed
Apr 1, 2026
Trade date
Mar 31, 2026
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 2 derivative transactions. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hamill John P.CIK 0001716213Officer (SrVP/CFO/Prin Fin & Acct Ofcr)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

This filing has no transactions of this kind.

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 31, 2026Common StockPPurchaseAcquired+30,978$0.81+$25,092.1830,978Direct
Mar 31, 2026Common StockPPurchaseAcquired+30,978–F1–30,978Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On March 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 30,978 shares of the Issuer's common stock ("Shares") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 30,978 Shares.

Referenced by the price of 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)